You don't think they need logistics support, support staff to assist and train the ATCs, support and training on how to handle the patients and assist with reimbursement. Sorry this ain't a pill you just sell to the doctors.
You are in dream land if you think NWBO can handle these. They have no commercialization experience let alone biotech experience in LP and LG. They have no plans for any commericialization strategy or hirings. If they were going to commercialize this, you would have seen at least one c suite hire with legitimate commercialization experience already and no not on the Advent Side. Even if by miracle this is approved, this ain't going anywhere. This motley crew has no shot in hell to manage this process. Be realistic. I've said it many time here before, there is no path to profitability here.
This has always been about enriching the c suite via the buildout of ceo owned CDMO, salaries/bonuses, and transfering nwbo shareholder $ to her web of related funds and companies. The sooner you realize this the better off you will be. They fooled the first set of investors via Cognate and now are fooling a whole new set of investors v2.0. They just changed the Exchange, the name and location of the CDMO because the first time worked so well. That is the reason for this long drawn out process....it's working to a charm AGAIN.
LC and IcLight bring up these issues over and over, but the sheep and the paid company pumpers do their best to sling mud their way. Almost as if the company has trained them how to respond....
AI
Market Data 
Markets 
